Investors & Media

Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization

With experienced commercial team in place, Ionis poised to independently bring steady cadence of potentially transformational RNA-targeted medicines to patients beginning in 2024 Plan to add four new wholly owned neurology medicines to clinical pipeline by end of 2024 Innovative technology advances

Read more
You are now leaving to visit